Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study.

@article{citeulike:2539849, abstract = {Frontotemporal dementia (FTD) represents an important cause for degenerative disruption and is increasingly recognized as an important cause (up to 25\%) of degenerative dementia among late-middle-age individuals. The serotoninergic system is tightly bound to frontal circuits, whose degeneration subserves FTD. Patients aged 64-68 years, with a diagnosis of FTD, were randomized to receive paroxetine up to 20 mg/day (n = 8) or piracetam up to 1,200 mg/day (n = 8). At 14 months, the patients treated with paroxetine showed significant improvements in behavioral symptoms, reflected by a reduction of caregiver stress. Side effects were easily tolerable, and there was no dropout. The results are presented with an overview of the literature on the topic.}, address = {Dipartimento di Fisiologia e Patologia, UCO di Neurologia, Universit\`{a} di Trieste, Italia. moretti@univ.trieste.it}, author = {Moretti, R. and Torre, P. and Antonello, R. M. and Cazzato, G. and Bava, A. }, citeulike-article-id = {2539849}, issn = {0014-3022}, journal = {Eur Neurol}, keywords = {frontotemporal\_dementia, ssri, treatment}, number = {1}, pages = {13--19}, posted-at = {2008-03-16 15:39:42}, priority = {5}, title = {Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/12464713}, volume = {49}, year = {2003} }

TY - JOUR ID - citeulike:2539849 L3 - citeulike-article-id:2539849 N2 - Frontotemporal dementia (FTD) represents an important cause for degenerative disruption and is increasingly recognized as an important cause (up to 25%) of degenerative dementia among late-middle-age individuals. The serotoninergic system is tightly bound to frontal circuits, whose degeneration subserves FTD. Patients aged 64-68 years, with a diagnosis of FTD, were randomized to receive paroxetine up to 20 mg/day (n = 8) or piracetam up to 1,200 mg/day (n = 8). At 14 months, the patients treated with paroxetine showed significant improvements in behavioral symptoms, reflected by a reduction of caregiver stress. Side effects were easily tolerable, and there was no dropout. The results are presented with an overview of the literature on the topic. IS - 1 JF - Eur Neurol SN - 0014-3022 AD - Dipartimento di Fisiologia e Patologia, UCO di Neurologia, Università di Trieste, Italia. moretti@univ.trieste.it EP - 19 TI - Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. VL - 49 SP - 13 KW - frontotemporal_dementia KW - ssri KW - treatment AU - Moretti, R AU - Torre, P AU - Antonello, RM AU - Cazzato, G AU - Bava, A PY - 2003/// UR - http://view.ncbi.nlm.nih.gov/pubmed/12464713 ER -